Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Yang, Zhang-Ru, Liu, Mi-Na, Yu, Jia-Hua, Yang, Yun-Hai, Chen, Tian-Xiang, Han, Yu-Chen, Zhu, Lei, Zhao, Ji-Kai, Fu, Xiao-Long, Cai, Xu-Wei
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2020
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653116/
https://ncbi.nlm.nih.gov/pubmed/33209626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados